Autopsy report · NCT02888756

iHIVARNA Clinical Trial in HIV Infected Individuals

“Interim analysis did not show sufficient immunogenicity of IMP compared to placebo”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 10 months before it stopped.
• 33 participants enrolled.
• Results were posted on the registry 1 year 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Rob Gruters

Sponsor type

University, hospital or other

Conditions

HIV Infections

Interventions

iHIVARNA-01; TriMix; Placebo

Participants

33

Sites

5

Countries

Belgium, Netherlands, Spain

Trials that died the same way

• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
  “Results of a planned interim analysis did not show significant effects for any of the 3 AIN dose regimens versus placebo on any primary or secondary endpoint” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.